Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 8.36 is 19% below its 5-year average of 10.30, near the low end of its 5-year range (0.40–52.78).
As of the fiscal period ended Tuesday, June 30, 2026. 13.58% below its 12-month average of 9.67.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 8.36.
CURRENT RATIO
8.36
CURRENT RATIO AVG TTM
9.67
CURRENT RATIO AVG 3Y
13.86
CURRENT RATIO AVG 5Y
10.30
CURRENT RATIO AVG 10Y
N/A
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-13.58%
CURRENT VS 3Y AVG
-39.71%
CURRENT VS 5Y AVG
-18.90%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.75
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+122.83%
vs the sector median at left
Market Cap
$533.04M
Current Ratio
33.56
TTM Avg
31.41
3Y Avg
17.80
5Y Avg
16.41
Market Cap
$529.58M
Current Ratio
27.59
TTM Avg
10.29
3Y Avg
10.12
5Y Avg
12.12
Market Cap
$548.51M
Current Ratio
1.92
TTM Avg
2.96
3Y Avg
5.58
5Y Avg
6.23
Market Cap
$524.43M
Current Ratio
25.13
TTM Avg
6.17
3Y Avg
7.34
5Y Avg
19.91
Market Cap
$557.32M
Current Ratio
9.36
TTM Avg
2.17
3Y Avg
1.76
5Y Avg
2.63
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ProKidney Corp. (PROK) | $538.01M | 8.36 | 9.67 | 13.86 | 10.30 |
| Monopar Therapeutics Inc. (MNPR)vs › | $533.04M | 33.56 | 31.41 | 17.80 | 16.41 |
| Delcath Systems, Inc. (DCTH)vs › | $531.98M | 9.83 | 11.46 | 6.57 | 5.79 |
| Nuvectis Pharma, Inc. (NVCT)vs › | $531.52M | 1.68 | 2.23 | 2.63 | 2.59 |
| Shattuck Labs, Inc. (STTK)vs › | $529.58M | 27.59 | 10.29 | 10.12 | 12.12 |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $548.51M | 1.92 | 2.96 | 5.58 | 6.23 |
| Immix Biopharma, Inc. (IMMX)vs › | $524.43M | 25.13 | 6.17 | 7.34 | 19.91 |
| Altimmune, Inc. (ALT)vs › | $519.25M | 26.78 | 15.83 | 15.06 | 15.09 |
| CytomX Therapeutics, Inc. (CTMX)vs › | $557.32M | 9.36 | 2.17 | 1.76 | 2.63 |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $516.76M | 3.46 | 4.63 | 6.00 | 6.13 |
Current Ratio
8.36
Quick Ratio
8.36
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 8.36 |
| 2026-03-31 | 9.06 |
| 2025-12-31 | 9.13 |
| 2025-09-30 | 10.32 |
| 2025-06-30 | 11.48 |
| 2025-03-31 | 10.96 |
| 2024-12-31 | 10.93 |
| 2024-09-30 | 17.09 |
| 2024-06-30 | 21.87 |
| 2024-03-31 | 17.62 |
| 2023-12-31 | 14.94 |
| 2023-09-30 | 19.37 |
| 2023-06-30 | 19.04 |
| 2023-03-31 | 42.57 |
| 2022-12-31 | 46.42 |
| 2022-09-30 | 52.78 |
| 2022-06-30 | 0.74 |
| 2022-03-31 | 1.10 |
| 2021-12-31 | 2.21 |
| 2021-09-30 | 0.82 |
| 2021-06-30 | 0.40 |
| 2021-03-31 | 0.00 |
| 2020-12-31 | 1.02 |
